hCG Group Research Articles

The effect of hormonal preparation (gonadotropins vs. gonadoliberins) on pre-seasonally obtained eggs and larvae quality in pikeperch (Sander lucioperca L.)

Although several papers were dealing with intensively reared broodstocks, most of the published artificial reproduction protocols were applied in wild pikeperch breeders. Therefore, we aimed to evaluate the effects of ovulation induction agents, namely human chorionic gonadotropin (hCG) and salmon gonadotropin–releasing hormone analogue (sGnRHa) on the reproductive performance in pre-seasonal artificial propagation of cultured pikeperch. Breeders were harvested from an outdoor in-pond circulation system in mid-September and transferred to indoor facility in late January, conditioned and injected with either 50 μg kg−1 of sGnRHa or 500 IU kg−1 of hCG, with six females in each hormonal group. Stripped eggs from each female were sampled for chemical composition analysis, fertilised with the milt of two males, incubated and obtained larvae were further reared. No significant differences were noticed between the treatments in any of the analysed parameters of embryo survival nor larviculture performance. Rather high differences in intragroup variation were seen between the treatments, expressed in several-fold higher coefficients of variation in embryo survival in experimental and commercial conditions in the hCG group. Eggs obtained from females treated with hCG had a significantly higher lipid content (31.1% ± 2.0%) compared to sGnRHa-treated females (27.4% ± 1.8%). Fatty acid profiles of the eggs revealed differences in total n − 6 and linoleic acid 18:2n − 6 content while n − 3/n − 6 was significantly lower in the hCG group. Gonadoliberins reduced the variability in the spawning outcome. It appears that hormones can modify the eggs’ fat content during the pre-season artificial reproduction.

Pregnancy outcomes with frozen-thawed single euploid blastocyst transfer following IVF cycles using HCG versus GNRH agonist trigger for final oocyte maturation

It is now well known that GnRH agonist (GnRHa) when used to trigger final oocyte maturation results in early luteolysis and consequently luteal phase dysfunction in fresh autologous IVF cycles. However, with the use of adjuvant low dose hCG, pregnancy outcomes are favorable and comparable to after hCG trigger(1). This suggests that GnRHa trigger does not impact oocyte or embryo quality. Furthermore, previous studies have shown comparable live birth rates after frozen-thawed embryo transfer (FET) cycles utilizing embryos obtained from cycles triggered previously with GnRHa versus hCG (2). Previous studies have also shown comparable euploid rates after GnRHa and hCG trigger (3). However, there are no studies evaluating pregnancy rates after transfer of euploid frozen embryos derived from cycles triggered with either GnRHa or hCG trigger. To compare pregnancy outcomes for frozen-thawed single euploid embryo transfer cycles that were generated from cycles triggered with either GnRHa or hCG. Retrospective cohort study done at a single academic IVF center evaluating frozen-thawed embryo transfer (FET) cycles in which single euploid blastocysts were transferred over a four year period. All embryos were generated in preceding fresh autologous IVF cycle in which hCG or GnRHa was used for final oocyte maturation. Embryos were subsequently transferred in a medicated or natural frozen cycle (44.3% medicated cycles in hCG group v. 37.0% in GnRHa group, p>0.05.) Patients were excluded if they had >1 embryo transferred, day 3 embryo biopsies, donor oocyte cycles or dual trigger with both hCG and GnRHa. Primary outcome was ongoing pregnancy rate or live birth rate (OPR/LBR) Secondary outcomes were clinical pregnancy rate (CPR), clinical loss rate (CLR) and multiple pregnancy rate (MPR.) Student’s t-test was used to analyze continuous variables and Chi Square test was used for categorical variables. Multivariate logistical regression was performed to control for potential confounding variables. A p-value of <0.05 was considered statistically significant. A total of 215 FET cycles were included for analysis (hCG trigger, n=115 subjects; GnRHa trigger, n=100 subjects.) The GnRHa group was significantly younger (34.8 years old v. 37.2 years old) and had higher baseline AMH values (4.55 ng/ml versus 2.1 ng/ml) than the hCG group, respectively (p<0.05.) There was no significant difference in OPR/LBR (60.9% v. 62.0%), CPR (68.7% v. 69.0%), CLR (8.9% v. 10.1%) or MPR (1.3% v. 2.9%) in the GnRHa v. hCG groups, respectively. Using logistic regression to control for the significant confounding variables of age and AMH value, the adjusted odds ratio for live birth was 1.09 (95% CI 0.60-1.99, p=0.77) when GnRHa trigger was compared to hCG trigger.Table 1Pregnancy Outcomes After Single Euploid Embryo Transfer in FET cycles Triggered by hCG or GnRHa Stratified by AgeAge Group<35 YO>35 YOAll PatientsPregnancy OutcomehCG (n=29)GnRHa (n=55)hCG (n=86)GnRHa (n=45)hCG (n=115)GnRHa (n=100)IR20/29 (69.0%)41/55 (74.5%)60/86 (69.8%)29/45 (64.4%)80/115 (69.6%)70/100 (70.0%)CPR19/29 (65.5%)41/55 (74.5%)60/86 (69.8%)28/45 (62.2%)79/115 (68.7%)69/100 (69.0%)OPR/LBR16/19 (55.2%)36/55 (65.5%)54/86 (62.8%)26/45 (57.8%)70/115 (60.9%)62/100 (62.0%)CLR3/19 (15.8%)5/41 (12.2%)6/60 (10.0%)2/28 (7.1%)9/79 (8.9%)7/69 (10.1%)MPR1/19 (5.3%)1/41 (2.4%)0/60 (0.0%)1/28 (3.6%)1/79 (1.3%)2/69 (2.9%)∗ There were no significant differences in any of the variables listed above (p>0.05) Open table in a new tab ∗ There were no significant differences in any of the variables listed above (p>0.05) Our findings confirm that euploid embryos created after hCG or GnRHa trigger have the same potential for pregnancy.

Different Thyroidal Responses to Human Chorionic Gonadotropin Under Different Thyroid Peroxidase Antibody and/or Thyroglobulin Antibody Positivity Conditions During the First Half of Pregnancy.

Thyroid peroxidase antibody (TPOAb) positivity can attenuate gestational thyroid responses to human chorionic gonadotropin (hCG) during pregnancy, whereas the effects of thyroglobulin antibodies (TgAb) remain unknown. The aim of our study was to explore the thyroid response to hCG in women with thyrotropin (TSH) levels within the method-specific reference range under different conditions of thyroid autoimmunity. The study screened 822 women at 7-20 weeks of gestation using the pregnancy-specific reference range for TSH. Serum TSH, free thyroxine (fT4), TPOAb, TgAb, and β-hCG levels were measured using electrochemiluminescence immunoassays. The enrolled pregnant women were subdivided into four subgroups based on TPOAb/TgAb positivity: co-positive for TPOAb and TgAb (group 1), isolated TPOAb positive (group 2), isolated TgAb positive (group 3), and co-negative for TPOAb and TgAb (group 4). TSH was negatively associated with hCG in all four groups (p < 0.05). fT4 was positively associated with hCG in groups 3 and 4 (p < 0.01) but not in groups 1 (p = 0.096) and 2 (p = 0.758). Group 2 was further stratified into tertiles according to TPOAb concentrations. No negative TSH/hCG association was observed in the middle- and upper-tertile groups when TPOAb were ≥53 IU/mL (p > 0.05). There was no positive fT4/hCG association in any of the three subgroups (p > 0.05). Similarly, group 3 was further stratified into tertiles according to TgAb levels. TSH was negatively associated with hCG in the lower and middle tertiles (p < 0.01), but the association was not found in the upper tertile when TgAb was ≥356 IU/mL (p = 0.191). fT4 was positively associated with hCG in the lower tertile (p = 0.027) but not in subgroups when TgAb was ≥219 IU/mL (p > 0.05). When TSH was within the pregnancy-specific reference range, high concentrations of TPOAb and TgAb attenuated the fT4 stimulation and suppression of TSH by hCG. The results imply that TgAb, in addition to TPOAb, could also interfere with thyroidal responses to hCG during the first half of pregnancy.

Effects of FSH and the weather during induced ovulation and timed artificial insemination to increase jenny conception rates

Experiments were conducted to improve jenny conception rates through induced ovulation and timed insemination. Jennies in control, hCG and LH groups were injected intramuscularly with saline alone or saline containing hCG or LH, respectively, when the dominant follicle diameter reached 35 mm. Then, follicle development was checked every 8 h until the dominant follicle ovulated. While 76% of the hCG-treated jennies ovulated between 24 and 48 h, and 84% of the LH-treated ovulated between 24 and 40 h after injection, ovulations in control jennies scattered over an extended period after injection. Conception rates after insemination were significantly higher in LH- or hCG-treated jennies than in the conventionally-bred jennies. The LH preparation used in this study contained more FSH than the hCG preparation did, and supplementing the hCG treatment with FSH significantly improved ovulation synchronization. Ovulations in jennies treated on rainy days were significantly postponed and less synchronized compared to those in jennies treated on sunny days. Together, the results suggested that jenny conception could be significantly improved by inducing ovulation with LH or hCG treatment followed by timed insemination and that FSH and the weather during treatment had profound effects on ovulation induction of jennies.

Gonadotrophin stimulation of ewes that are not pregnant following multiple matings during the season

In this study, the aim was to obtain pregnancy following synchronization and to increase profitability in ewes that did not become pregnant during the breeding season after at least 3 matings. Nonpregnant Middle Anatolian Merino ewes (n = 117) were given a progesterone sponge for 9 days. At the time of sponge removal, the ewes received 250 IU pregnant mare serum gonadotropin (PMSG) + 125 µg prostaglandin F2α (PGF2α). Two days later, they were injected with either human chorionic gonadotropin (hCG) (Group I, n = 48) or gonadotropin-releasing hormone (GnRH) (Group II, n = 43), or remained as a control (Group III, n = 26). The ewes were allowed to mate at estrus following the PGF2α injection. Pregnancy diagnosis was performed on day 30 after mating by ultrasonography. Group ratios for estrus (58.3%, 55.8%, 53.8%), conception (78.6%, 87.5%, 14.3%), lambing (90.9%, 90.5%, 50.0%), multiple births (15.0%, 31.6%, 0.0%), and average lamb number for birth (1.15%, 1.31%, 1.0%) were reported. In conclusion, the gonadotropin-supplemented protocols used here were found to be useful in ewes that were not pregnant after multiple matings during the breeding season in increasing the profitability of flocks with this problem.

Role of Human Chorionic Gonadotrophin Compared to 17-Alpha-Hydroxyprogesterone in the Management of Threatened Abortion: Experience in a Military Hospital in Dhaka, Bangladesh

Background: Threatened abortion is the most common complication in the first half of gestation. Spontaneous abortion occurs in less than 30% of the women who experience threatened abortion. In order to prevent pregnancy loss several supportive therapies including hormonal therapy like human chorionic gonadotropin (hCG) or 17-alpha-hydroxyprogesterone (progesterone) have been advocated. The exogenous administration of hCG is aimed at stimulating and therefore optimizing progesterone production. Aim of this study was to compare the efficacy of supportive therapy with hCG and progesterone in women with threatened abortion.&#x0D; Methods: This prospective study was carried out in the department of obstetrics and gynecology of the Combined Military hospital (CMH), Savar, Dhaka, Bangladesh from July 2016 to June 2017. One hundred pregnant patients admitted with the history of per vaginal bleeding before 20 weeks of gestation without having any other co-morbidity were included in this study. Patients were randomized to two treatment groups. The participants in group A (52, 52%) received injection hCG weekly while those in group B (48, 48%) received injection progesterone from recruitment up until 20 weeks of gestation. Further USG were performed one week and four weeks after recruitment to the study and again at 20 weeks and subsequently when indicated. The final outcome of pregnancy were recorded and analyzed.&#x0D; Results: Among 100 patients majority belonged to the 26-30 year age group. Mean age of the patients was 27.2±10.5 years. There was not much significant difference between the groups in terms of parity. More than 75% of patients in both the groups presented before 16 weeks of gestation with threatened abortion. In both the groups more than 75% of the patients had previous history of pregnancy loss. In terms of pregnancy outcome more patients in hCG group had live pregnancy than progesterone group (88.5% vs 66.7%) (p=0.012). Out of 46 live birth in hCG group, 4 (7.7%) were preterm labor between 31-35 weeks of pregnancy and one baby died in neonatal ICU, one died at 31 weeks of gestation which was delivered by vaginally. On the other hand out of 32 live birth in progesterone group, there was 3 (6.3%) preterm labor. Growth retardation was less in hCG group compared to progesterone group (9.6% vs 14.6%). However cesarean section rate was high in both the groups.&#x0D; Conclusion: Treatment with injection hCG has better pregnancy outcome than that of injection17-alphahydroxyprogesterone in early pregnancy with threatened abortion of unexplained cause.&#x0D; Birdem Med J 2019; 9(1): 7-10

Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers

BackgroundFertility preservation (FP) protocols in case of breast cancer (BC) include mature oocyte cryopreservation following letrozole associated controlled ovarian hyperstimulation (Let-COH). To date, the impact of Let-COH on the follicular microenvironment has been poorly investigated, although a high androgen/estrogen ratio was previously associated with low oocyte quality.MethodsIn this prospective study, follicular fluid (FF) steroid levels (estradiol, testosterone, progesterone) and cumulus cell (CC) gene expression related to oocyte quality (HAS2, PTGS2, GREM1) were compared between 23 BC patients undergoing Let-COH for FP and 24 infertile patients undergoing conventional COH without letrozole. All patients underwent an antagonist COH cycle, and ovulation was triggered with hCG or GnRHa in both groups.ResultsFF estradiol levels were significantly lower while testosterone levels were significantly higher in the study group compared to controls irrespective of the trigger method. However, estradiol levels increased significantly with GnRHa triggering compared to hCG in the study group (median = 194.5 (95.4–438) vs 64.4 (43.8–152.4) ng/ml, respectively, p < 0.001), but not in the control group (median = 335.5 (177.5–466.7) vs 354 (179–511) ng/ml, respectively). After hCG trigger, Cumulus cell (CC) gene expression was lower in the study group compared to the control group, and difference was significant for PTGS2. Conversely, CC gene expression of PTGS2 and GREM1 was significantly higher in the study group compared to controls when ovulation was triggered with GnRHa.ConclusionsLet-COH triggered with hCG may negatively impact oocyte quality. However, ovulation triggering with GnRHa may improve the oocyte microenvironment and cumulus cell genes expression in Let-COH, suggesting a positive impact on oocyte quality in breast cancer patients.Trial registrationClinicaltrials.gov -NCT02661932, registered 25 January 2016, retrospectively registered.

Взаимосвязь между андрогенным дефицитом и ослаблением чувствительности аденилатциклазы к гонадотропинам в семенниках крыс со стрептозотоциновым диабетом различной степени тяжести

Type 1 diabetes mellitus (DM1) leads to dysfunctions of the male reproductive system, which is caused by a decrease in testosterone (T) synthesis by the testes. Currently, there is little studied how the severity of DM1 affects the T production, and what role in the development of androgen deficiency is played by a decrease in the sensitivity of the adenylyl cyclase system of Leydig cells to gonadotropins. The aim of the work was to study the basal and human chorionic gonadotropin(hCG)-stimulated T levels in male rats with severe, moderate and mild forms of DM1, as well as to study the regulation of the enzyme adenylyl cyclase (AC) by non-hormonal agents (forskolin, GppNHp) and hCG in the testicular membranes of diabetic rats. The severe (D-T) and moderate (D-S) forms of DM1 were caused by treatment of four-month-old rats with streptozotocin at the doses of 60 and 35 mg/kg, and the mild form (D-M) was induced by treatment of five-day-old rat pups with streptozotocin (75 mg/kg), which led to the development of diabetes at the age of 4 months. The values ​​of AUC(11.00-18.00) (the integrated area under the curve “concentration of T(nM) –time(h)”) in the D-T, D-S and D-M groups was 50.4±10.4, 75.7±21.2 and 105.9±9.3 arb.u. and were reduced by 69, 53 and 34% in comparison with control (161.1±18.6 arb.u., p<0.05). The AUC(11.00-16.00) for the T level stimulated by hCG (100 IU/rat) in the same groups were 115.4±30.4, 229.6±64.3 and 306.4±58.8 arb.u. and were reduced by 74, 48 and 31% in comparison with control (445.4±132.7 arb.u., p<0.05). In the testicular membranes of rats of the D-T group, the basal and the forskolin-, GppNHp- and hCG-stimulated AC activity were decreased by 34, 39, 54 and 68%, respectively. In the D-S and D-M groups, only the AC effects of GppNHp and hCG were decreased. Thus, the androgen deficiency in rats with DM1 and the steroidogenic response in the case of their treatment with hCG depend on the severity of DM1, and the key cause of the androgen deficiency is the impaired functional activity of the gonadotropin-sensitive adenylyl cyclase system in the testes of diabetic rats.

Testosterone undecanoate supplementation together with human chorionic gonadotropin does not impair spermatogenesis in males with isolated hypogonadotropic hypogonadism: a retrospective study.

Gonadotropin therapy is commonly used to induce virilization and spermatogenesis in male isolated hypogonadotropic hypogonadism (IHH) patients. In clinical practice, 5.6%–15.0% of male IHH patients show poor responses to gonadotropin treatment; therefore, testosterone (T) supplementation can serve as an alternative therapy to normalize serum T levels and promote virilization. However, treatment with exogenous T impairs spermatogenesis and suppresses intratesticular T levels. This retrospective study aimed to determine whether oral testosterone undecanoate (TU) supplementation together with human chorionic gonadotropin (hCG) would negatively affect spermatogenesis in IHH patients compared with hCG alone. One hundred and seven IHH patients were included in our study. Fifty-four patients received intramuscular hCG and oral TU, and 53 patients received intramuscular hCG alone. The median follow-up time was 29 (range: 12–72) months in both groups. Compared with the hCG group, the hCG/TU group required a shorter median time to normalize serum T levels (P < 0.001) and achieve Tanner stage (III and V) of pubic hair and genital development (P < 0.05). However, there were no significant differences in the rate of seminal spermatozoa appearance, sperm concentration, or median time to achieve different sperm concentration thresholds between the groups. In addition, there were no significant differences in side effects, such as acne and gynecomastia, observed in both groups. This study indicates that oral TU supplementation together with hCG does not impair spermatogenesis in treated IHH patients compared with hCG alone, and it shortens the time to normalize serum T levels and promote virilization.

192 The use of human chorionic gonadotropin seven days after synchronized estrus for the increase of luteal tissue in Morada Nova ewes

The study was performed to evaluate whether the use of hCG 7 days after synchronized oestrus in Morada Nova ewes would increase the number and size of corpora lutea. Multiparous Morada Nova ewes (n=115, mean weight of 36.6kg, body condition score 3.13 on 1 to 5 scale) were used. Oestrus was synchronized by using an intravaginal sponge impregnated with medroxyprogesterone acetate (60mg, Progespon®, Zoetis, Parsippany, NJ, USA) for 6 days and eCG (200IU, IM Novormon®, Zoetis) plus PGF2α analogue (37.5μg, D-cloprostenol, IM, Vetglan®, Hertape Calier, Spain), both administered 24h before the sponge removal. Seven days after the synchronized oestrus, hCG (300IU, IM, Vetecor®, Hertape Calier; n=57) or normal saline (control group, 1mL, IM, 0.9% NaCl, Eurofarma Laboratory SA, Sao Paulo, Brazil; n=58) was injected. B-mode ultrasound examinations of the ovaries were performed using the equipment MyLab Vet 30 Gold (Esoate, Genoa, Italy) on Day 7 (corresponding to the day of hCG or physiological solution administrations), and 6 days later (Day 13). The number of corpora lutea present and the size of luteal tissue (sum of diameter and area) were determined. Data were analysed by ANOVA with Tukey’s post hoc test (mean±s.e.m.) using SAS software (SAS Institute Inc., Cary, NC, USA). On Day 7, the number of corpora lutea was similar (P&amp;gt;0.05) between the hCG and control groups (1.58±0.09v. 1.57±0.08, respectively); however, the number was higher on Day 13 (P&amp;lt;0.05) in the hCG group (2.65±0.13) than in the control group (1.69±0.07). Similarly, there was no difference (P&amp;gt;0.05) between groups in diameter (16.9±0.82v. 16.0±0.71mm) and area (1.61±0.07v. 1.45±0.06cm2) for hCG and control groups, respectively, on Day 7. Differences were observed on Day 13, such that the hCG ewes had luteal tissue of larger (P&amp;lt;0.0001) diameters (27.13±1.25v. 18.44±0.85mm) and area (2.81±0.13v. 1.71±0.08cm2) than ewes of the control group. In conclusion, 300IU of hCG injected 7 days after synchronized oestrus is effective to increase the number of corpora lutea and in the size of luteal tissue. Despite indications of a favourable effect on luteal dynamics, the effects on progesterone production and conception rate need to be examined. This study was supported by CNPq and EMBRAPA (process no. 02.13.06.026.00.02).

Effect of GnRH or hCG administration on Day 4 post insemination on reproductive performance in Merino sheep of North Patagonia

Different therapeutic strategies have been used with the objective of improve luteal function to reduce embryonic losses. The objective of this work was to study the effect of the administration of GnRH or hCG at Day 4 post fixed time artificial insemination (FTAI) on reproductive efficiency in Merino sheep during the breeding season in North Patagonia. Estrus of multiparous Merino ewes (n = 288) was synchronized by two injections of prostaglandins (PG; 125 μg, Cloprostenol), 14 days apart. Cervical FTAI was performed 53–56 h after the second PG with a dose of fresh semen (100 × 106 spermatozoa) from five Merino rams. In all ewes body condition score (BCS) was determined at FTAI. At 4 days post FTAI ewes were randomly assigned into three experimental groups: GnRH group (4 μg, Buserelin; n = 99), hCG group (300 IU, hCG; n = 92) and Control group (1 ml, saline solution; n = 97). Pregnancy and pregnancy losses were evaluated by ultrasonography on Days 33 and 90 post FTAI. Additionally, embryo crown-rump length (CRL) was measured by ultrasonography (n = 12 single-pregnant ewes by experimental group) at the first ultrasound. Date of birth, litter size and lamb weight were recorded (n = 111 pregnant ewes). Pregnancy rate on Days 33 and 90 post FTAI did not differ among treatment groups (P > 0.05). Pregnancy losses at Day 33 post FTAI were lower in the hCG group compared to the GnRH and Control groups (0, 3, 7.2%, respectively; P < 0.05). Pregnancy losses between Days 33 and 90 after FTAI were negligible (P > 0.05). The embryo CRL at Day 33 post FTAI was not increased by the hormonal treatments (P > 0.05). Moreover, it was lower in GnRH group compared to Control group (P < 0.05). Litter size tended to be greater in the GnRH group compared to the hCG and Control groups (P < 0.1). The birth weight of twin lambs tended to be higher in the GnRH group compared to the Control group (P < 0.1). The birth weight of single lambs was not affected by treatments (P > 0.05). Ram fertility and BCS of ewes at FTAI influenced the effect of hormonal treatments on reproductive parameters. In conclusion, administration of hCG or GnRH at Day 4 post FTAI does not improve pregnancy rate but treatment with hCG reduces pregnancy loss on Day 33 post FTAI. GnRH treatment improves litter size and twin lambs birth weight.

Increased implantation rate after intrauterine infusion of a small volume of human chorionic gonadotropin at the time of embryo transfer: a randomized, double-blind controlled study.

Intrauterine human chorionic gonadotropin (hCG) infusion at the time of embryo transfer (ET) has resulted in controversial results. We evaluated the effects of intrauterine infusion of a small volume of hCG at the time of ET in fresh and frozen-thawed cycles. Infertile women scheduled for ET with either fresh or frozen-thawed cycles were enrolled and randomized into two groups (n = 100 each): an hCG group, who received 500IU of hCG in 10 µL culture medium infused into the uterine cavity using a soft catheter 4min before ET; and a control group, who received 10 µL of culture medium alone by the same technique. The primary outcome was the implantation rate. The secondary outcomes were clinical pregnancy and live birth rate. Two hundred infertile women aged 18-43years, undergoing fresh or frozen-thawed ET were enrolled, regardless of any previous transfer cycles. The implantation rate was significantly higher in the hCG group compared with the control group (28.8% vs. 18.2%, p = 0.030). The clinical pregnancy rates were similar in both groups (42% vs. 30%, p = 0.077). The live birth rates were also similar (29% and 23% in the hCG and control group, respectively). Intrauterine infusion of a small volume of hCG at the time of ET can significantly improve the implantation rate, while the clinical pregnancy rate may only be improved in younger patients (aged < 40years). This technique may thus be of benefit to patients undergoing clinical infertility treatment.

Inducing ovulation with hCG in a five-day progesterone-based fixed-time AI protocol improves the fertility of anestrous dairy cows under heat stress conditions

This study compares the fertility effects of inducing ovulation using human chorionic gonadotropin (hCG) versus gonadotropin releasing hormone (GnRH) at the end of a 5-day progesterone(P4)-based protocol for fixed-time artificial insemination (FTAI) in heat-stressed and non-heat stressed anestrous lactating dairy cows. Heat stress (HS) was defined as an environmental temperature-humidity index (THI) > 72. A P4 intravaginal device (CIDR) was fitted for five days and GnRH administered upon CIDR insertion and a double dose (24 h apart) of prostaglandin F2α upon CIDR removal. Cows then received either GnRH (GnRH group; n = 506), or hCG (hCG group; n = 493) 36 h after CIDR removal and were inseminated 50–56 h after CIDR removal. Ovulation failure was investigated in a subset of 425 cows: 223 and 202 receiving GnRH and hCG, respectively. Based on odds ratios, the interaction between treatment and HS had a significant effect on the ovulation failure rate (P = 0.01). This meant that compared to the rates recorded in non-heat-stressed, GnRH-treated cows (13%), ovulation failure in heat-stressed GnRH-treated cows (25.3%) was more likely by a factor of 2.3 (P = 0.04), in non-heat-stressed hCG-treated cows (2.3%) was less likely by a factor of 0.16 (P = 0.02) and was not significantly different in heat-stressed hCG-treated cows (7%). Interactions between treatment and HS and between treatment and parity had a significant effect on the pregnancy rate (P = 0.0001 and P = 0.001, respectively). The treatment-HS interaction determined that compared to the rates recorded in non-heat-stressed, GnRH-treated cows (30.5%), pregnancy in heat-stressed GnRH-treated cows (17.6%) was less likely by a factor of 0.48 than the remaining cows (P = 0.001), whereas because of the treatment-parity interaction, compared to the rates recorded in primiparous, GnRH-treated cows (31.4%), pregnancy in GnRH-treated multiparous cows (18.9%) was less likely to conceive by a factor of 0.51 than the remaining cows (P = 0.002). No significant effects of treatment on the rates of pregnancy loss or twin pregnancy were identified by binary logistic regression. In conclusion, hCG treatment given at the end of a 5-day P4-based protocol for FTAI improved ovulation and pregnancy rates in anestrous cows under conditions of HS and also had a beneficial impact on the pregnancy rate in anestrous multiparous cows throughout the year.

Effect of intrauterine injection of human chorionic gonadotropin before fresh embryo transfer on IVF and ICSI outcomes: a meta-analysis

PurposeThis analysis was performed to evaluate the effects of intrauterine injection of human chorionic gonadotropin (hCG) before fresh embryo transfer (ET) on the outcomes of in vitro fertilization and intracytoplasmic sperm injection.MethodsRandomized controlled trials (RCTs) were identified by searching electronic databases. The outcomes of live birth, clinical pregnancy, implantation, biochemical pregnancy, ongoing pregnancy, ectopic pregnancy, and miscarriage between groups with and without hCG injections were analyzed. Summary measures were reported as risk ratios (RR) with 95% confidence intervals.ResultsSix RCTs on fresh embryo transfer (ET) were included in the meta-analysis. A total of 2759 women undergoing fresh ET were enrolled (hCG group n = 1429; control group n = 1330). Intrauterine injection of hCG significantly increased rates of biochemical pregnancy (RR 1.61) and ongoing pregnancy (RR 1.58) compared to controls. However, there were no significant differences in clinical pregnancy (RR 1.11), implantation (RR 1.17), miscarriage (RR 0.91), ectopic (RR 1.65) or live birth rates (RR 1.13) between the hCG group and control group.ConclusionThe current evidence for intrauterine injection of hCG before fresh ET does not support its use in an assisted reproduction cycle.

Role of Ozone Therapy in Preventing Testicular Damage in an Experimental Cryptorchid Rat Model.

BackgroundCryptorchidism is the most common developmental abnormality of the male reproductive system. If left untreated, it results with infertility and testicular cancer. According to current evidence, surgery is the mainstay of treatment, and hormonal therapy approaches are still under investigation. For the protection of testicular functions, antioxidants have emerged as novel options. This study aimed to evaluate the protective properties of ozone, a strong antioxidant, on testicular tissue.Material/MethodsThirty-five male Wistar-albino rats, 1-month-old, were used for the study. Groups were formed as follows: 1) control, 2) sham surgery (cryptorchidism), 3) cryptorchidism plus ozone, 4) cryptorchidism plus human chorionic gonadotropin (hCG), and 5) ozone plus hCG. Surgical procedures were performed on all rats except the control group. All rats except the control group were used to create an experimental cryptorchidism model, and left testes of animals were surgically placed into the abdomen. After 1 month of surgery, groups 3, 4, and 5 were given corresponding treatments intraperitoneally for 4 weeks. At the end of the study period, testicular atrophy index (TAI) and testicular sperm motility (TSM) were assessed and biochemical, histopathological, and immunohistochemical tests were performed.ResultsTAI and TSM were higher in the ozone, hCG, and ozone plus hCG groups than in the sham surgery group (p=0.001). TSM in the ozone group was significantly higher than in the hCG and ozone plus hCG groups. In biochemical analyses, the parameters of oxidative stress (GPx1, MDA, CAT, GSH, SOD) indicated increased oxidative activity in cryptorchidism, which was resolved by applying ozone and hCG (p=0.001). In addition, apoptotic markers, Caspase 3 and bcl-2 were significantly decreased by applying ozone and hCG (p=0.001).ConclusionsResults of this study suggest that ozone therapy, either as a single agent or in combination with hCG, is a promising approach for protection of testicular functions.

ECG stimulation in domestic cats increases the expression of gonadotrophin-induced genes improving oocyte competence during the non-breeding season.

The objective of this study was to evaluate the eCG stimulation on domestic cat oocyte competence during the non-breeding season. Four experimental groups were made: (a) untreated cycling cats (Breeding season group; BS), (b) untreated anestrous cats (Non-breeding group; NB), (c) anestrous cats treated with 200IU of eCG (eCG group) and (d) anestrous cats treated with 200IU of eCG and 100IU of hCG four days later (hCG group). In the BS, NB and eCG groups, grade I and II immature cumulus-oocyte complexes (COCs) were subjected to in vitro maturation or used for the gene expression analysis of FSHR, LHCGR, EGFR, EGR1, ESR2, PTGS2, GDF9, BMP15 and GATM. The in vitro matured oocytes from the BS, NB and eCG groups and the in vivo matured oocytes from the hCG group were subjected to parthenogenetic activation. The grade I and II COCs from the eCG group had an increased expression of FSHR, LHCGR, EGFR, EGR1 and ESR2 and a higher maturation rate than the BS and NB groups (p<0.05). After parthenogenetic activation, the blastocyst rate from the hCG, eCG and BS groups was higher than the NB group (p<0.05). However, no significant improvement was observed in the blastocyst rate in the hCG group compared to the eCG group (p>0.05). In conclusion, the eCG treatment increases the expression of specific genes improving the oocyte competence during the cat non-breeding season, which is reflected in an enhanced in vitro maturation and in vitro embryo development after parthenogenetic activation.

Efficacy of GnRH agonist trigger in women having history of follicular-endometrial asynchrony with clomiphene/IUI cycles in unexplained infertility.

An alternative option to human chorionic gonadotropin (hCG) is GnRH agonist (GnRH-a) for ovulation trigger in intrauterine insemination (IUI) cycles. This study aims to compare the efficacy of GnRH-a with hCG in women with history of follicular-endometrial asynchrony after clomiphene in IUI cycles. This prospective observational study recruited 631 women with unexplained infertility and follicular-endometrial asynchrony (follicle ≥ 18mm, endometrial thickness (ET) < 7mm) in previous two failed clomiphene/IUI cycles. Overall 27 patients with synchronized follicular-endometrial relationship and 49 women with persistent ET < 7mm and/or follicle > 26mm were excluded. Remaining women (n = 555) were divided into two groups: Group A (n = 285) received GnRH-a and Group B (n = 270) received hCG ovulation trigger. Finally, 513 patients, who underwent IUI, were analysed. Cancellation due to luteinized unruptured follicle was more in hCG group (P = 0.01). Higher clinical pregnancies (10.33 vs. 4.96%, P = 0.03) and live birth rates (8.86 vs. 4.13%, P = 0.03) were noted with GnRH-a trigger. Miscarriage rate was comparable in both the groups (10.71 and 16.67% in Group A and Group B, respectively). In unexplained infertility, GnRH agonist is an useful alternative for triggering ovulation in women with follicular-endometrial asynchrony following clomiphene induction.

Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study.

To compare serum testosterone response and symptom improvement in men with hypogonadism in response to treatment with clomiphene citrate (CC), human chorionic gonadotropin (hCG), or a combination of both therapies. A total of 282 men with hypogonadism, wishing to preserve their fertility, were randomized to one of three treatment arms: CC 50mg (n = 95); 5000IU hCG injections twice weekly (n = 94); or a combination of both therapies (CC + hCG; n = 94). All participants had complete medical history and had undergone thorough physical examination, including body mass index (BMI) assessment. Laboratory tests included serum total testosterone and glycated haemoglobin (HbA1c) measurements. Quantitative Androgen Deficiency in the Aging Male (qADAM) questionnaire scores were also recorded. Morning samples of total serum testosterone levels were assessed at three time points: baseline, 1 and 3months. Testosterone levels increased at 1 and 3months in all three groups. The mean baseline testosterone level was 2.31 ± 0.66nmol/L, BMI was 30.8 ± 6.2kg/m2 , and qADAM score was 20.5 ± 3.8. Testosterone levels increased in allgroups at all time points, with a final mean value of 5.17 ± 1.77nmol/L (223% increase) with no statistically significant difference among the groups. qADAM scores had increased in all groups at 1month (CC group: 6.36; hCG group: 5.08; CC + hCG group: 7.26) and at 3months (CC group: 12.73; hCG group: 11.82; CC + hCG group: 15.13) with a significant difference in intergroup analysis for the CC + hCG group compared with the other two groups (P < 0.01). All three treatments were equally effective in restoring testosterone levels. Single-agent CC is simple, cheap and may be used as treatment for hypogonadism when maintenance of fertility is desired. This approach seems to be as effective as either hCG alone or a combination of hCG and CC.

Effects of 17β-estradiol, Interleukin-1β, and Human Chorionic Gonadotropin on Activity and mRNA Expression of Plasminogen Activators in Porcine Endometrial Cells.

This study aimed to investigate changes in the activity and mRNA expression of plasminogen activators (PAs) induced by 17β-estradiol (E2), human chorionic gonadotropin (hCG), and interleukin-1β (IL-1β) in porcine endometrial cells. Endometrial cells were isolated from the epithelium and cultured to 80% confluence. They were then treated for 24 h with E2 (0.2, 2, 20, and 200 ng/mL), IL-1β (0.1, 1, 10, and 100 ng/mL), and hCG (0.5, 1, 1.5 and 2 IU/mL). mRNA expressions of urokinase-type (uPA) and tissue-type (tPA) PAs were analyzed using reverse transcription PCR, and activities were measured using a PA activity assay. mRNA expressions of uPA and tPA increased with E2 treatment; however, this was not significant. Similarly, treatment with hCG did not influence the mRNA expressions of PAs. Interestingly, treatment with 0.1 ng/mL IL-1β significantly reduced the mRNA expression of uPA, but did not affect that of tPA. Treatment with 2, 20, and 200 ng/mL E2 increased PA activity compared with the control group; treatment with 0.1 and 1 ng/mL IL-1β significantly increased PA activity compared with the other IL-1β treatment groups, whereas treatment with 10 and 100 ng/mL IL-1β decreased. Treatment with 2 IU/mL hCG increased PA activity compared with the other treatment groups, although there were no significant differences between the hCG and control groups. In conclusion, the activity and mRNA expression of PAs were differently regulated by the hormone/cytokine and its concentration in porcine endometrial cells. Therefore, understanding PA regulatory mechanisms may help to improve the reproductive potential of domestic animals.

Induction of Ovulation in Mangalarga Marchador Mares by hCG or GnRH

Background: Induction of ovulation is a key procedure for horse assisted reproduction technologies, such as for artificial insemination (AI) and embryo transfer. The application of hCG remains as the primary ovulation-inducing agent for horse assisted reproduction, but alternatives are in demand to avoid its adverse effects, such as loss of ovulation-inducing ef­ficiency over multiple applications by hCC-antibody production. Despite reports on alternative ovulation-inducing agents, pair-wise comparisons of such agents under similar conditions have been limited. Under such scenario, the work was aimed to determine the efficiency of both hCG and Buserelin at inducing ovulation in Mangalarga Marchador mares raised in the Northeast of Brazil under an AI program.Materials, Methods &amp; Results: Mares were initially selected based on their reproductive performance, the absence of clinical-reproductive alterations and adequate body condition score. Mares in diestrus were randomly distributed in three experimental conditions, received 5 mg of Dinoprost and were monitored daily for estrus detection. After estrus detection, ovaries were monitored by ultrasonography, in 12-h intervals, until the follicle reached 35 mm. At this time-point, ovula­tion was induced with 0.042 mg of Buserelin endovenously, with 3,000 IU hCG by an intramuscular shot, and control mares received 2 mL of saline solution, also by an intramuscular shot. Both hCG and Buserelin displayed similar efficien­cies (P &gt; 0.05) for induction of ovulation and that both agents were effective (P &lt; 0.05) for such purpose, since greater percentages (P &lt; 0.05) of induction on mares treated from those of the control. Moreover, the total number of ovulations in mares treated at the end of the experiment was not different (P &gt; 0.05) from those found in the Control. All ovulations occurred within a 72-h period after treatment. It can be observed that in mares treated with hCG or Buserelin, ovulations occurred both in more mares (P &lt; 0.05) and at earlier time-points than mares from the control. It is also possible to note that pregnancy was not different (P &gt; 0.05) between hCG and Buserelin groups, and that pregnancy of mares treated with ovulation-inducing factors was similar to the control.Discussion: The majority of ovulations in mares occurred within initial 48-h after treatment for both hCG and GnRH, suggesting a similar potential for horse assisted reproduction. Both hCG and Buserelin are two commonly used agents for induction of ovulation in mares. As described here, the majority of ovulations occurred within initial 48-h after treatment, a fact which can be attributed to hCG and GnRH activity, since it can happen in intervals from 36 to 48-h after treatment. Pregnancy rates did not differ among groups. These results are under the working hypothesis that hCG and Buserelin would display similar efficiencies on pregnancy rates. Despite the understanding of hCG activity on induction of ovulation due to its high specificity toward LH receptors and results from a direct effect on diminishing estradiol concentration, increasing LH, and further inducing ovulation within 48-h after treatment. In contrast, Buserelin has a similar functional property but acts upon LH synthesis and its release. In conclusion, ovulation in mares can be induced with both hCG and Buserelin, and both ovulation-inducing agents do not affect pregnancy rates.Keywords: gonadotropin, releasing factor, ovary, follicle, corpus luteum.